The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
Doshi
Ami
A
D000014:Abnormalities, Drug-Induced / Q000517:prevention & control; D000152:Acne Vulgaris / Q000188:drug therapy; D016907:Adverse Drug Reaction Reporting Systems / Q000295:instrumentation; D000075202:Contraindications; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D004335:Drug and Narcotic Control / Q000266:history; D005260:Female; D005333:Fetus; D017408:Guidelines as Topic; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage / Q000009:adverse effects / Q000600:supply & distribution / Q000627:therapeutic use; D007885:Legislation, Pharmacy; D008297:Male; D008431:Maternal-Fetal Exchange; D010593:Pharmaceutical Services / Q000592:standards; D011247:Pregnancy / Q000187:drug effects; D043762:Reproductive Behavior; D012308:Risk Management / Q000379:methods / Q000458:organization & administration / Q000639:trends; D012871:Skin Diseases / Q000188:drug therapy; D011049:Social Control Policies / Q000191:economics; D014481:United States; D014486:United States Food and Drug Administration
D015474:Isotretinoin